Login with ORCID

assertion

Full identifier: http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs#assertion

Minted in Nanopublication

 RA_oI-ncug comment approve/disapprove edit as derived nanopublication

This is a local identifier minted within the nanopublication. http://purl.org/np/RA_oI-ncug...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA_oI-ncug... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA_oI-ncug...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal)
.

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Elif Ozkan
2022-10-11T07:14:02.124Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
2022-10-11T07:14:02.124516
Elif Ozkan
2022-10-11T07:14:02.124Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40%. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. It is indicated for the management of essential. essential. heart failure.
Elif Ozkan
2022-10-11T07:14:02.124Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)